Christopher Ray Aker J.D.
Net Worth
Last updated:
What is Christopher Ray Aker J.D. net worth?
The estimated net worth of Mr. Christopher Ray Aker J.D. is at least $2,835,043 as of 18 Jan 2024. He owns shares worth $80,951 as insider, has earned $9,272 from insider trading and has received compensation worth at least $2,744,820 in Regulus Therapeutics Inc..
What is the salary of Christopher Ray Aker J.D.?
Mr. Christopher Ray Aker J.D. salary is $457,470 per year as Senior Vice President, Gen. Counsel & Corporation Sec. in Regulus Therapeutics Inc..
How old is Christopher Ray Aker J.D.?
Mr. Christopher Ray Aker J.D. is 64 years old, born in 1961.
What stocks does Christopher Ray Aker J.D. currently own?
As insider, Mr. Christopher Ray Aker J.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Regulus Therapeutics Inc. (RGLS) | Senior Vice President, Gen. Counsel & Corporation Sec. | 10,056 | $8.05 | $80,951 |
What does Regulus Therapeutics Inc. do?
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Christopher Ray Aker J.D. insider trading
Regulus Therapeutics Inc.
Mr. Christopher Ray Aker J.D. has made 14 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 5,468 units of RGLS stock worth $6,512 on 18 Jan 2024.
The largest trade he's ever made was exercising 6,950 units of RGLS stock on 15 May 2019. As of 18 Jan 2024 he still owns at least 10,056 units of RGLS stock.
Regulus Therapeutics key executives
Regulus Therapeutics Inc. executives and other stock owners filed with the SEC:
- Mr. Christopher Ray Aker J.D. (64) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Joseph P. Hagan M.B.A. (56) Pres, Chief Executive Officer & Director